LaNova Medicines Announces Global Exclusive License Agreement with Merck for LM-299, an Investigational Anti-PD-1/VEGF Bispecific Antibody

2024-11-14
Share:

SHANGHAI, November 14^{th, 2024 – LaNova Medicines Ltd. announced that it has entered into an exclusive global license agreement with Merck (NYSE: MRK), known as MSD outside of the United States and Canada, to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody.}

Previous

LaNova Medicines Initiates Pivotal Clinical Trial for LM-108 in China
Next

LaNova Medicines Completes USD 42 Million Series C1 Financing to Accelerate Clinical Progress and Innovation Platform Development